CANSINO BIOLOGICS IN

6185
End-of-day quote. End-of-day quote  - 09/24
280.2HKD -0.64%

Solution Biologics Sdn Bhd Signs Finished Product and a Bulk Product Agreement with Cansino Biologics Inc for the Supply of the Recombinant Ad5-Ncov Vaccine for Use Against the Covid-19 Virus

07/30/2021 | 01:07am
Solution Group Berhad's wholly-owned subsidiary, Solution Biologics Sdn Bhd, has signed a finished product and a bulk product agreement with CanSino Biologics Inc. for the supply of the Recombinant Ad5-nCoV vaccine for use against the COVID-19 virus. The finished product agreement allows SOLBIO to purchase and CanSino to supply the finish product vaccine for emergency use in Malaysia. Meanwhile, the bulk agreement will see CanSino supply the active pharmaceutical ingredients for the fill and finish ("F&F") to SOLBIO. Both agreements come with a period of ten (10) years with immediate effect.
© S&P Capital IQ 2021
Copier lien
All news about CANSINO BIOLOGICS INC.
2d ago
6d ago
09/10
09/07
09/07